To include your compound in the COVID-19 Resource Center, submit it here.

BCI-952: Phase II data

A modified intent-to-treat (mITT) analysis of 134 patients in a double-blind, U.S. Phase II trial showed that BCI-952 met the co-primary endpoint of

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE